PT - JOURNAL ARTICLE AU - CAIO BEZERRA MACHADO AU - EMERSON LUCENA DA SILVA AU - BEATRIZ MARIA DIAS NOGUEIRA AU - MANOEL ODORICO DE MORAES FILHO AU - RAQUEL CARVALHO MONTENEGRO AU - MARIA ELISABETE AMARAL DE MORAES AU - CAROLINE AQUINO MOREIRA-NUNES TI - PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology AID - 10.21873/anticanres.15014 DP - 2021 May 01 TA - Anticancer Research PG - 2397--2402 VI - 41 IP - 5 4099 - http://ar.iiarjournals.org/content/41/5/2397.short 4100 - http://ar.iiarjournals.org/content/41/5/2397.full SO - Anticancer Res2021 May 01; 41 AB - Background/Aim: Experimental oncology commonly uses cells as oncological models, providing a framework for the testing of drugs, and investigation of cytotoxicity, mutagenesis and carcinogenesis. Investigations into poly-ADP-ribose polymerase 1 (PARP1) inhibition have become ever more relevant due to its approval as a therapeutic option for tumors with BRCA1/2 DNA repair-associated mutation and the seemingly high PARP expression levels in some tumor subtypes. In this study, we aimed to determine PARP1 gene expression of different hematological cancer-derived cell lineages and compare them to that of normal cell lines. Materials and Methods: PARP1 gene expression in seven different neoplastic lineages, representing three different hematological disorders (chronic myeloid leukemia, Burkitt lymphoma and acute lymphoblastic leukemia), was quantified by quantitative real-time polymerase chain reaction. Results: All hematological malignant lineages in this study overexpressed PARP1 when compared to the normal cell line MRC-5, with Burkitt’s lymphoma cells having the highest expression values (fold change: 93). Conclusion: Overexpression of PARP1 in hematological malignant lineages is a finding of crucial importance to future studies exploring possible cellular oncogenic pathways and supports investigations into the effectiveness of PARP1 inhibitors against hematological disorders.